deucravacitinib,apremilast
bms,amgen
['$bmy', 'bristol']
bristol myers squibb announces new sotyktu long-term data showing clinical efficacy maintained for up to two years with continuous treatment in moderate-to-severe plaque psori.. $bmy 
Run by investors, for investors.

Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more

Not investment advice